Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $117,050.10 in Stock

Posted by Geri Gentry on Aug 16th, 2026

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) EVP Jason Daly sold 6,613 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $17.70, for a total transaction of $117,050.10. Following the transaction, the executive vice president owned 245,171 shares of the company’s stock, valued at approximately $4,339,526.70. The trade was a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $18.15 on Friday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of 37.04 and a beta of 1.27. The company’s fifty day moving average is $17.24 and its two-hundred day moving average is $14.59. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.20 and a 52-week high of $19.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AMRX shares. UBS Group lifted their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Buy” and a consensus price target of $17.67.

Read Our Latest Stock Report on AMRX

Institutional Trading of Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. bought a new position in Amneal Pharmaceuticals during the fourth quarter worth about $26,000. Federated Hermes Inc. boosted its holdings in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the period. Transamerica Financial Advisors LLC grew its stake in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the period. Finally, Focus Partners Wealth acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $42,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.